Hallura

Company Overview

Snapshot

Founded in August 2017 by Stephane Meunier, Hallura operates with 11–50 employees. The company has raised $7 million across two funding rounds from two investors. In November 2022, Hallura introduced its BiOLinkMatrix HA dermal fillers, inspired by "Click Chemistry" concepts, signaling a new generation of aesthetic medicine products.

Business overview

Hallura is developing a technology platform for next-generation hyaluronic acid (HA) dermal fillers for aesthetic medicine. The company's products are designed to address limitations of existing solutions by using a proprietary cross-linking technology that protects natural HA long chains. Hallura serves the aesthetic medicine market, focusing on non-invasive treatments for skin lifting, and operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Cosmetic Materials.

Strategic signal

In November 2022, Hallura launched its BiOLinkMatrix HA dermal fillers, inspired by "Click Chemistry" concepts. This development indicates the company's focus on advancing aesthetic medicine through novel cross-linking mechanisms, aiming to deliver soft, natural, and non-invasive treatments. For investors, this signals Hallura's commitment to innovation and its potential to capture a significant share in the growing market for advanced dermal fillers.

Company Intelligence Q&A

What is Hallura's core product innovation?

Hallura's core innovation is its proprietary cross-linking technology for hyaluronic acid (HA) dermal fillers, which uses a novel mechanism to maintain and protect natural HA long chains. This technology underpins its BiOLinkMatrix HA aesthetic dermal fillers.

When did Hallura announce its BiOLinkMatrix HA dermal fillers?

Hallura announced its BiOLinkMatrix HA dermal fillers, inspired by "Click Chemistry" concepts, in November 2022.

What were the results of Hallura's European multi-site clinical trial?

In March 2022, Hallura announced successful topline results from its European multi-site clinical trial for its new BiOLinkMatrix HA aesthetic dermal fillers.

Who was appointed to Hallura's Board of Directors in 2020?

In July 2020, Hallura announced the appointment of Paul Navarre to its Board of Directors.

What was the outcome of Hallura's in vivo animal studies?

Hallura has completed a full set of in vivo animal studies for its products, demonstrating excellent safety and a higher potential for skin lifting compared to other leading products currently on the market.